Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The long-term effect of Onabotulinum Toxin A for drooling control in Children.
EF 2013-14
Résumé
Background: Drooling or excessive flow of saliva can have many medical complications such as choking, aspiration and skin breakdown as well psychosocial issues in a population where the majority are patients with neurological disabilities (e.g Cerebral Palsy, Down’s syndrome). There are several modalities for the management of drooling including medication, rehabilitation therapy and the removal of salivary glands that produce saliva. A novel option has been the usage of Onabotulinum Toxin A (Botox® - OBTXA) injections. This method reduces salivation, but its effect is transient and various injections are required. Objective: To assess the efficacy of repetitive use of OBTXA in salivary glands of children for the treatment of hypersalivation. To determine whether OBTXA is a good long term solution for drooling control. Materials and methods: The first part will be the recruitment and follow-up of patients to build a data base to compare the long term effect of OBTXA in one cohort. Salivary glands will be measured by ultrasound guidance in 4 sessions, each scheduled every 3 months. The second part will evaluate the Quality of Life (QOL) after 1 year of follow-up. We will be using a validated QOL questionnaire used by our clinic, comprising 25 questions completed by the child’s parent/legal guardian. The third part will assess the medical charts of patients, comparing the structure of salivary glands from children who received OBTXA and had their salivary glands removed with those whose gland was removed without any OBTXA use for drooling control. The sample tissues will be derived from surgeries performed previously by the same Otolaryngologist. Relevance: We are the only clinic in the province of Quebec specialized in the treatment of drooling and a pioneer in this technique with hundreds of children injected over a five year period. It is important for us to ascertain that there are no side effects with prolonged used of OBTXA injection.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311909
Name
Cardona ISABEL
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The long-term effect of Onabotulinum Toxin A for drooling control in Children.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cerebral Palsy; Developmental Delay; Drooling; Histopathology; Management; Onabotulinum Toxin A; Pediatrics; Salivary Glands; Sialorrhea; Ultrasound
Abstract
Background: Drooling or excessive flow of saliva can have many medical complications such as choking, aspiration and skin breakdown as well psychosocial issues in a population where the majority are patients with neurological disabilities (e.g Cerebral Palsy, Down’s syndrome). There are several modalities for the management of drooling including medication, rehabilitation therapy and the removal of salivary glands that produce saliva. A novel option has been the usage of Onabotulinum Toxin A (Botox® - OBTXA) injections. This method reduces salivation, but its effect is transient and various injections are required. Objective: To assess the efficacy of repetitive use of OBTXA in salivary glands of children for the treatment of hypersalivation. To determine whether OBTXA is a good long term solution for drooling control. Materials and methods: The first part will be the recruitment and follow-up of patients to build a data base to compare the long term effect of OBTXA in one cohort. Salivary glands will be measured by ultrasound guidance in 4 sessions, each scheduled every 3 months. The second part will evaluate the Quality of Life (QOL) after 1 year of follow-up. We will be using a validated QOL questionnaire used by our clinic, comprising 25 questions completed by the child’s parent/legal guardian. The third part will assess the medical charts of patients, comparing the structure of salivary glands from children who received OBTXA and had their salivary glands removed with those whose gland was removed without any OBTXA use for drooling control. The sample tissues will be derived from surgeries performed previously by the same Otolaryngologist. Relevance: We are the only clinic in the province of Quebec specialized in the treatment of drooling and a pioneer in this technique with hundreds of children injected over a five year period. It is important for us to ascertain that there are no side effects with prolonged used of OBTXA injection.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cardona, ISABEL
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~